𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Changes in the Vif protein of HIV-1 associated with the development of resistance to inhibitors of viral protease

✍ Scribed by Melanie A. Adekale; Patricia A. Cane; Malcolm A. McCrae

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
621 KB
Volume
75
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The protease (PR) and virus infectivity factor (vif) gene sequences of a cohort of HIV‐1 infected patients showing evidence of developing protease inhibitor (PI) resistance whilst undergoing highly active antiretroviral therapy (HAART) have been determined. The PR sequences showed the presence of the classical mutations associated with resistance to PIs. The sequence of the Vif protein showed less variation in samples from PI treated patients than in specimens prepared from treatment‐naïve patients. In addition a number of amino acid positions within Vif showed highly significant preferences for a particular amino acid in the PI‐treated cohort compared to the untreated control cohort. J. Med. Virol. 75:195–201, 2005. © 2004 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Subtype diversity associated with the de
Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors
✍ Bluma G. Brenner; Matthew Lowe; Daniela Moisi; Isabelle Hardy; Simon Gagnon; Hug 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB

## Abstract We used genotypic and phylogenetic analysis to determine integrase diversity among subtypes, and studied natural polymorphisms and mutations implicated in resistance to integrase inhibitors (INI) in treatment‐naïve persons (n = 220) and ‐experienced individuals (n = 24). Phylogenetics r

Longitudinal use of phenotypic resistanc
Longitudinal use of phenotypic resistance testing to HIV-1 protease inhibitors in patients developing HAART failure
✍ Jean Servais; Jean-Marc Plesséria; Christine Lambert; Elodie Fontaine; Isabelle 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## Abstract An “in‐house” recombinant virus protease inhibitor susceptibility assay was carried out (median of 3 per patient) retrospectively in 26 patients failing HIV protease inhibitor based therapy at regular intervals to the initiation of the first protease inhibitor. Patients were treated wit